Safety of pregnancy after discontinuation of isotretinoin

Dai, W. S.

doi:10.1001/archderm.125.3.362

Cited by 18 publications

(12 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The frequency of congenital anomalies does not appear to be increased among children of women who discontinue therapy before conception. 85 These medications are contraindicated during pregnancy and among women planning a pregnancy (FDA category X). Etretinate persists in the body for an extremely long time after administration, and the length of time that teratogenic effects may occur is currently not known.…”

Section: Vitamin a Cogeners/retinoidsmentioning

confidence: 99%

Noninherited Risk Factors and Congenital Cardiovascular Defects: Current Knowledge

Jenkins¹,

Correa²,

Feinstein³

et al. 2007

Circulation

696

336

View full text Add to dashboard Cite

Abstract-Prevention of congenital cardiovascular defects has been hampered by a lack of information about modifiable risk factors for abnormalities in cardiac development. Over the past decade, there have been major breakthroughs in the understanding of inherited causes of congenital heart disease, including the identification of specific genetic abnormalities for some types of malformations. Although relatively less information has been available on noninherited modifiable factors that may have an adverse effect on the fetal heart, there is a growing body of epidemiological literature on this topic. This statement summarizes the currently available literature on potential fetal exposures that might alter risk for cardiovascular defects. Information is summarized for periconceptional multivitamin or folic acid intake, which may reduce the risk of cardiac disease in the fetus, and for additional types of potential exposures that may increase the risk, including maternal illnesses, maternal therapeutic and nontherapeutic drug exposures, environmental exposures, and paternal exposures. Information is highlighted regarding definitive risk factors such as maternal rubella; phenylketonuria; pregestational diabetes; exposure to thalidomide, vitamin A cogeners, or retinoids; and indomethacin tocolysis. Caveats regarding interpretation of possible exposure-outcome relationships from case-control studies are given because this type of study has provided most of the available information. Guidelines for prospective parents that could reduce the likelihood that their child will have a major cardiac malformation are given. Issues related to pregnancy monitoring are discussed. Knowledge gaps and future sources of new information on risk factors are described.

show abstract

Section: Vitamin a Cogeners/retinoidsmentioning

confidence: 99%

Noninherited Risk Factors and Congenital Cardiovascular Defects: Current Knowledge

Jenkins¹,

Correa²,

Feinstein³

et al. 2007

Circulation

696

336

View full text Add to dashboard Cite

show abstract

“…Some reports have indicated that isotretinoin side‐effects can continue even >4 weeks after discontinuation . Women who became pregnant one cycle after completing therapy are believed to be at teratogenic risk no higher than baseline . For both single and multiple doses, the observed accumulation ratios of isotretinoin range from 0.90 to 5.43 in patients with cystic acne .…”

Section: Discussionmentioning

confidence: 99%

Congenital microtia in a neonate due to maternal isotretinoin exposure 1 month before pregnancy: Case Report

Shirazi

Abbariki

Pirjani

et al. 2015

J of Obstet and Gynaecol

View full text Add to dashboard Cite

Isotretinoin is a drug used for treating severe cystic/nodular acne. Severe malformations have been documented in neonates whose mothers had taken isotretinoin during pregnancy. Women who became pregnant one cycle after completing therapy are believed to be at teratogenic risk not higher than baseline. We describe the case of a newborn whose mother had taken the drug for 4 weeks. The woman then had contraception for 4 weeks (after the drug treatment had finished), and became pregnant after that period. The newborn had isolated bilateral microtia due to suspected isotretinoin exposure. His mother also had a history of urine tract infection in the second week of pregnancy that was treated with cephalexin. The parents were not from a consanguineous marriage and had no family history of congenital malformations. To reduce the risk, effective contraception should be continued in fertile women more than 1 month after completing therapy.

show abstract

“…Acne and Acneiform Eruptionscycle after completely stopping isotretinoin is advised in a published guideline [17]. But on the contrary, many cases of unwanted pregnancies and relevant abortuses have been reported all over the world [18].…”

Section: Isotretinoinmentioning

confidence: 99%

Acneiform Eruptions and Pregnancy

Kaptanoğlu¹,

Mullaaziz²

2017

Acne and Acneiform Eruptions

View full text Add to dashboard Cite

Acne and acneiform eruptions during pregnancy need special attention. The physician should be aware of the special condition of a pregnant patient. Acne treatments may aim to prevent worsening, secondary infections, scarring and lowering self-esteem of the mother. However, the treatment of acne and acneiform eruptions are not easy to treat during pregnancy. First, because many cosmetics and procedures are not tested on pregnant patients and it is impossible to predict the possible consequences of the procedures on fetus, many women quit cosmetic procedures during pregnancy. Second, the underlying conditions such as hormonal influx and immunosuppression continue. Third, the medications for acne have limitations due to the lack of evidence of safety during pregnancy. Here, a acneiform eruptions during pregnancy, including acne vulgaris, acne rosacea, perioral dermatitis, and hidradenitis suppurativa, are reviewed focusing on these points and each of them is evaluated by clinical presentation, differential diagnosis and treatment options focusing on maternal and fetal safety.

show abstract

Safety of pregnancy after discontinuation of isotretinoin

Cited by 18 publications

References 0 publications

Noninherited Risk Factors and Congenital Cardiovascular Defects: Current Knowledge

Noninherited Risk Factors and Congenital Cardiovascular Defects: Current Knowledge

Congenital microtia in a neonate due to maternal isotretinoin exposure 1 month before pregnancy: Case Report

Acneiform Eruptions and Pregnancy

Contact Info

Product

Resources

About